510(k) device
Elecsys sFlt-1 and Elecsys PlGF
Roche Diagnostics · Prognostic Test For Development Or Progression Of Preeclampsia (QWH, Class II) · First FDA decision Feb 7, 2025, newest Feb 7, 2025Pregnancy, labor and postpartum hemorrhage
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "Elecsys sFlt-1"
MAUDE reports
2
Brand "Elecsys sFlt-1", since 2015
PubMed studies
23
Mentioning "Elecsys sFlt-1"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Elecsys sFlt-1 and Elecsys PlGF
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Elecsys sFlt-1 and Elecsys PlGFBreakthrough510(k)
K241453 · Decided Feb 7, 2025 · 261 days after receipt
Device type: Prognostic Test For Development Or Progression Of Preeclampsia (QWH) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Elecsys sFlt-1", any status and sponsor, newest update first.
No registered device study names "Elecsys sFlt-1".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Elecsys sFlt-1", and for the whole product code for context.
This brand
2 reports: 2 malfunction, 0 injury, 0 death
Whole product code QWH
2 reports: 2 malfunction, 0 injury, 0 death
Newest reports for this brand
- ELECSYS SFLT-1Malfunction
1823260-2025-02221 · Received Jul 21, 2025 · Event dated Jun 27, 2025
Device type: Prognostic Test For Development Or Progression Of Preeclampsia (QWH)
Device problem as coded: Incorrect Measurement
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- ELECSYS SFLT-1Malfunction
1823260-2025-00587 · Received Feb 28, 2025 · Event dated Feb 2, 2025
Device type: Prognostic Test For Development Or Progression Of Preeclampsia (QWH)
Device problem as coded: Low Test Results; Non Reproducible Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Elecsys sFlt-1"[tiab]. The summary above synthesizes these.
- Economic Impact Analysis of Incorporation of Elecsys sFlt-1/PlGF Ratio Into Routine Practice for the Diagnosis and Follow-Up of Pregnant Women With Suspected Preeclampsia in Argentina.
Garay OU, Guiñazú GG, Basualdo N, et al. · Value Health Reg Issues · 2023
- Analytical Performance and Quality Indicators of Fully Automated Immunoassays for sFlt-1 and PlGF.
Higgins V, Ma L, Ragosnig BL, et al. · J Appl Lab Med · 2022Research Support, Non-U.S. Gov't
- Predictive Value of the sFlt-1/PlGF Ratio and Interleukin-6 for the Presence of Placental Lesions in Spontaneous Preterm Labor with Intact Membranes with Delivery within 7 Days.
Kacerovsky M, Hornychova H, Holeckova M, et al. · Fetal Diagn Ther · 2024
- sFlt-1/PlGF ratio for prediction of preeclampsia in clinical routine: A pragmatic real-world analysis of healthcare resource utilisation.
Dathan-Stumpf A, Rieger A, Verlohren S, et al. · PLoS One · 2022Research Support, Non-U.S. Gov't
- Clinical usefulness of angiogenic factors in women with chronic kidney disease and suspected superimposed preeclampsia.
Molina-Pérez CJ, Nolasco-Leaños AG, Carrillo-Juárez RI, et al. · J Nephrol · 2022Research Support, Non-U.S. Gov't
- Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia.
Schiettecatte J, Russcher H, Anckaert E, et al. · Clin Biochem · 2010Evaluation Study, Multicenter Study
- Angiogenic imbalance in pregnancies with preterm prelabor rupture of membranes between 34 and 37ߙweeks of gestation.
Kacerovsky M, Hornychova H, Jaiman S, et al. · Acta Obstet Gynecol Scand · 2024
- Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study.
McCarthy FP, Gill C, Seed PT, et al. · Ultrasound Obstet Gynecol · 2019Comparative Study
- Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia--the PreOS study protocol.
Hund M, Verhagen-Kamerbeek W, Reim M, et al. · Hypertens Pregnancy · 2015Multicenter Study, Research Support, Non-U.S. Gov't
- Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia.
Frusca T, Gervasi MT, Paolini D, et al. · J Matern Fetal Neonatal Med · 2017
- Markedly higher sFlt-1/PlGF ratio in a woman with acute fatty liver of pregnancy compared with HELLP syndrome.
Suzuki H, Nagayama S, Hirashima C, et al. · J Obstet Gynaecol Res · 2019Comparative Study
- Increased serum levels of sFlt-1/PlGF ratio in preeclamptic women with onset at <32 weeks compared with ࣙ32 weeks.
Suzuki H, Hirashima C, Nagayama S, et al. · Pregnancy Hypertens · 2018Comparative Study
Other devices of this type
Also filed under product code QWH.
- B·R·A·H·M·S sFlt-1/ PlGF KRYPTOR Test SystemBrahms GmbH, Part of Thermo Fisher Scientific · De Novo 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.